Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
Vaximm AG, a subsidiary of OSR Holdings (NASDAQ: OSRH), Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm’s leadership with deep, long-standing expertise in the company’s core technology.
Vaximm Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones
OSR Holdings, Inc. (NASDAQ: OSRH) announced that its subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG for a global exclusive license for its lead immunotherapy candidate, VXM01. Per the agreement, BCM Europe intends to establish and manage a dedicated investment vehicle, which would act as the formal Licensee.
Vaximm AG Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months
OSR Holdings, Inc. (NASDAQ: OSRH) provided an update regarding the previously announced non-binding term sheet between its subsidiary, Vaximm AG, and BCM Europe AG. The parties have agreed to shorten the exclusivity period from six months to three months, reflecting the strong alignment and confidence between Vaximm and BCME in advancing a definitive exclusive global licensing agreement for VXM01.
Vaximm AG Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones
OSR Holdings, Inc. (NASDAQ: OSRH) announced that Vaximm AG, an OSR Company, has entered into a non-binding term sheet with BCM Europe AG, a Swiss-based life sciences investment group and OSRH’s largest shareholder, to explore a potential exclusive global licensing agreement for VXM01, Vaximm’s first-in-class oral cancer immunotherapy platform.
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
OSR Holdings, Inc. (NASDAQ: OSRH) announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2.
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Vaximm AG, a subsidiary of OSR Holdings, Inc., announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01 in combination with PD-L1 inhibitor in patients with recurrent glioblastoma.